Untersuchung der mesodermalen Entwicklungskapazität induzierter pluripotenter Stammzellen generiert aus humanen mesenchymalen Stammzellen mit dem Ziel, eine unbegrenzte mesenchymale Zellquelle für das muskuloskelettale Tissue Engineering zu generieren.
Zusammenfassung der Projektergebnisse
The presented iPS data strongly indicates that mesenchymal progenitors generated from PSCs via spontaneous differentiation are not identical to primary mesenchymal stem cells but are rather at a more primitive developmental stage. Therefore, it seems to be highly recommended to clearly distinguish MSCs from PSC-derived mesenchymal progenitors, e.g. by denominating them EMP and iMP, respectively. Since iMP quality and general characteristics were not markedly dependent on the derivation method, for future use in regenerative medicine the most cost- and time-effective as well as experimentally easiest method seems to be favorable. Direct treatment of PSC cultures with serum-containing media or with chemically defined media supplemented with appropriate cytokines, or even EB outgrowth cultures might therefore be preferable over co-culture with mouse cell lines. To direct E/iMPs into lineage-specific differentiation and generate tissue constructs applicable for regenerative medicine calls for more sophisticated approaches than MSCs, but their general capacity to form various tissues has been proven. The true attractiveness of iMPs for therapeutic application is that they can easily be derived in virtually unlimited amounts. Moreover, the somatic origin of iPSCs allows for autologous cell derivation, thus avoiding the legal and ethical constraints associated with ESCs.
Projektbezogene Publikationen (Auswahl)
- “Mesenchymal progenitors derived from human induced pluripotent stem cells” Abstract at the 3rd TERMIS (Tissue Engineering & Regenerative Medicine International Society) World Congress 2012. September 5-8, 2012. Vienna, Austria. J Tissue Eng Regen Med. 2012 Sep;6 Suppl 1:1-465
Diederichs S, Tuan RS
- "The promise and challenges of stem cell-based therapies for skeletal diseases: Stem cell applications in skeletal medicine: Potential, cell sources and characteristics, and challenges of clinical translation." Bioessays. 2013 Mar;35(3):220-30
Diederichs S, Shine KM, Tuan RS
